Esperion Therapeutics Inc. (NASDAQ:ESPR) reported fourth-quarter adjusted earnings per share of $0.22 on Tuesday, falling short of the analyst consensus estimate of $0.29. Revenue, however, came in at $168.4 million, slightly above the $168.28 million expected by analysts.
Shares of the company jumped 8.22% in pre-market trading following the results, supported by strong revenue growth and the announcement of an agreement to acquire Corstasis Therapeutics.
Total revenue for the fourth quarter surged 144% year over year from $69.1 million in the same period a year earlier. For the full year 2025, revenue rose 21% to $403.1 million, compared with $332.3 million in 2024.
U.S. net product revenue increased about 38% year over year to $43.7 million in the quarter, matching the full-year growth rate of 38%, which brought annual U.S. product revenue to $159.6 million. Collaboration revenue for the quarter totaled $124.7 million and included a one-time $90 million payment from Otsuka following regulatory approval and favorable pricing decisions in Japan.
“2025 was a defining year for Esperion. We delivered strong growth in our U.S. cardiovascular franchise, broadened access and adoption among statin intolerant or statin-resistant patients and strengthened the durability of our business,” said Sheldon Koenig, Chief Executive Officer of Esperion.
Retail prescription equivalents in the fourth quarter increased 34% year over year and rose 11.3% sequentially.
Esperion reported net income of $61.8 million for the quarter, compared with a net loss of $21.3 million in the same period last year. For the full year 2025, the company recorded a net loss of $22.7 million, narrowing from a loss of $51.7 million in 2024.
The company also announced plans to acquire Corstasis Therapeutics, the developer of Enbumyst, the first FDA-approved nasal spray diuretic used to treat edema associated with congestive heart failure.
Looking ahead, Esperion expects operating expenses in fiscal 2026 to range between $225 million and $255 million, including roughly $15 million in non-cash stock-based compensation.